Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 2
1964 1
1966 1
1969 1
1970 3
1971 3
1975 1
1976 1
1978 1
1979 1
1980 3
1981 2
1982 1
1983 1
1984 3
1985 4
1986 6
1987 5
1988 3
1989 3
1990 4
1992 3
1993 5
1994 7
1995 5
1996 11
1997 6
1998 8
1999 2
2000 6
2001 8
2002 4
2003 5
2004 3
2005 10
2006 10
2007 12
2008 16
2009 7
2010 10
2011 14
2012 13
2013 19
2014 24
2015 36
2016 38
2017 37
2018 28
2019 26
2020 31
2021 14
Text availability
Article attribute
Article type
Publication date

Search Results

437 results
Results by year
Filters applied: . Clear all
Page 1
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL; KEYNOTE-240 investigators. Finn RS, et al. Among authors: ogasawara s. J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2. J Clin Oncol. 2020. PMID: 31790344 Clinical Trial.
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.
Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Omata M, et al. Among authors: ogasawara s. Hepatol Int. 2017 Jul;11(4):317-370. doi: 10.1007/s12072-017-9799-9. Epub 2017 Jun 15. Hepatol Int. 2017. PMID: 28620797 Free PMC article. Review.
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Zhu AX, et al. Among authors: ogasawara s. Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Lancet Oncol. 2018. PMID: 29875066 Clinical Trial.
Correspondence.
Ogasawara S, Chiba T, Ooka Y, Yokosuka O, Kato N. Ogasawara S, et al. Hepatology. 2018 Sep;68(3):1207-1208. doi: 10.1002/hep.30110. Hepatology. 2018. PMID: 29901217 No abstract available.
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group. Kudo M, et al. Among authors: ogasawara s. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7. Lancet Gastroenterol Hepatol. 2018. PMID: 29631810 Clinical Trial.
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
Ogasawara S, Ooka Y, Itokawa N, Inoue M, Okabe S, Seki A, Haga Y, Obu M, Atsukawa M, Itobayashi E, Mizumoto H, Sugiura N, Azemoto R, Kanayama K, Kanzaki H, Maruta S, Maeda T, Kusakabe Y, Yokoyama M, Kobayashi K, Kiyono S, Nakamura M, Saito T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N. Ogasawara S, et al. Invest New Drugs. 2020 Feb;38(1):172-180. doi: 10.1007/s10637-019-00801-8. Epub 2019 Jun 6. Invest New Drugs. 2020. PMID: 31172442
Switching to systemic therapy after locoregional treatment failure: Definition and best timing.
Ogasawara S, Ooka Y, Koroki K, Maruta S, Kanzaki H, Kanayama K, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Kato N. Ogasawara S, et al. Clin Mol Hepatol. 2020 Apr;26(2):155-162. doi: 10.3350/cmh.2019.0021n. Epub 2020 Jan 15. Clin Mol Hepatol. 2020. PMID: 31937081 Free PMC article. Review.
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Ueshima K, Ogasawara S, Ikeda M, Yasui Y, Terashima T, Yamashita T, Obi S, Sato S, Aikata H, Ohmura T, Kuroda H, Ohki T, Nagashima K, Ooka Y, Takita M, Kurosaki M, Chayama K, Kaneko S, Izumi N, Kato N, Kudo M, Omata M. Ueshima K, et al. Among authors: ogasawara s. Liver Cancer. 2020 Sep;9(5):583-595. doi: 10.1159/000508724. Epub 2020 Jul 24. Liver Cancer. 2020. PMID: 33083282 Free PMC article.
Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma.
Maruta S, Ogasawara S, Ooka Y, Obu M, Inoue M, Itokawa N, Haga Y, Seki A, Okabe S, Azemoto R, Itobayashi E, Atsukawa M, Sugiura N, Mizumoto H, Koroki K, Kanayama K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N. Maruta S, et al. Among authors: ogasawara s. Liver Cancer. 2020 Aug;9(4):382-396. doi: 10.1159/000507022. Epub 2020 May 5. Liver Cancer. 2020. PMID: 32999866 Free PMC article.
437 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page